IMNM
Immunome, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow -1.6% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | 0 | 68.26M | $1.45B | +7 | −7 |
| Q1 2026 | 85 | +8 | 69.87M | $1.52B | +12 | −4 |
| Q4 2025 | 77 | -1 | 71.18M | $1.53B | — | −1 |
| Q3 2025 | 17 | 0 | 44.21M | $517.66M | +1 | −1 |
| Q2 2025 | 14 | -2 | 33.29M | $309.62M | — | −2 |
| Q1 2025 | 13 | 0 | 18.78M | $126.42M | +1 | −1 |
| Q4 2024 | 13 | +3 | 9.20M | $97.76M | +3 | — |
| Q3 2024 | 9 | -2 | 5.86M | $85.63M | — | −2 |
| Q2 2024 | 11 | — | 5.95M | $72.02M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 2.04M | +0.8% | $29.77M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.04M | +0.8% | $29.77M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Marshall Wace ✦ | 1.47M | -14.3% | $21.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 1.47M | -14.3% | $21.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.21M | +13.6% | $17.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.21M | +13.6% | $17.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 470.65K | +22.2% | $6.88M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | PRIMECAP Management ✦ | 280.80K | +4.5% | $4.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 220.00K | 0.0% | $3.22M | 0.0% | Held | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 140.69K | +137.1% | $2.06M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 140.69K | +137.1% | $2.06M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 21.98K | +36.8% | $321,333 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 11.30K | -87.9% | $165,206 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $1.30M | was 0.0% |
| Citadel Advisors | $50,421 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 35.50K shares, $776 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 11.05K sh · $301,058
Director · 62.29K sh · $1.63M
Director · 10.12K sh · $263,959
Director · 15.25K sh · $397,363
Director · 20.84K sh · $543,090
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology